Skip to main content
Help
Log In
Sign Up
Home
Watchlist
Stocks
Stock Screener
Stock Exchanges
Comparison Tool
Earnings Calendar
By Industry
Stock Lists
Top Stocks
Corporate Actions
IPOs
Recent IPOs
IPO Calendar
IPO Lockups
IPO Statistics
IPO News
IPO Screener
ETFs
ETF Screener
Comparison Tool
New Launches
ETF Providers
Analysts
News
Trending
Private Companies
Technical Chart
Fundamental Chart
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After Hours
Market Heatmap
Market Newsletter
Stock Analysis Pro
Tools
Collapse
Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
Full Chart
Watchlist
Alerts
Compare
110.40
-1.16 (-1.04%)
At close:
Sep 30, 2026, 4:00 PM EDT
110.00
-0.40 (-0.36%)
After-hours:
Sep 30, 2026, 7:58 PM EDT
Overview
Financials
Forecast
Statistics
Metrics
History
Profile
Chart
Metrics
Revenue by Segment
Operating Expense Breakdown
Halozyme Therapeutics Revenue by Segment
Quarterly
TTM
Download
Period Ending
Jun 30, 2026
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Royalties
1.04B
940.33M
867.84M
780.29M
699.31M
618.59M
570.99M
522.62M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Royalties Growth
49.06%
52.01%
51.99%
49.30%
45.09%
31.95%
27.49%
21.04%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Product Sales
476.94M
428.83M
376.44M
333.14M
325.57M
322.95M
303.49M
303.73M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Product Sales Growth
46.49%
32.78%
24.04%
9.68%
7.22%
8.14%
0.88%
7.55%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Revenues Under Collaborative Agreements
144.41M
139.30M
152.33M
129.42M
153.79M
142.77M
140.84M
121.00M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Revenues Under Collaborative Agreements Growth
-6.10%
-2.43%
8.16%
6.96%
75.42%
49.45%
74.88%
81.95%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Operating Expense Breakdown
Period Ending
Jun 30, 2026
Mar 31, 2026
Dec 31, 2025
Sep 30, 2025
Jun 30, 2025
Mar 31, 2025
Dec 31, 2024
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Cost of Sales
292.42M
259.61M
228.77M
192.06M
186.24M
179.49M
159.42M
169.66M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Cost of Sales Growth
57.01%
44.64%
43.51%
13.20%
6.39%
-3.25%
-17.13%
-6.87%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Selling, General, and Administrative
238.00M
222.61M
207.09M
172.31M
167.47M
161.56M
154.34M
149.69M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Selling, General, and Administrative Growth
42.12%
37.79%
34.18%
15.11%
16.52%
9.94%
3.45%
0.25%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Research and Development
102.37M
92.25M
81.49M
70.03M
71.24M
74.74M
79.05M
79.94M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Research and Development Growth
43.70%
23.44%
3.09%
-12.40%
-9.60%
-3.56%
3.52%
3.03%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Amortization
100.16M
88.41M
76.66M
71.05M
71.05M
71.05M
71.05M
71.05M
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Amortization Growth
40.98%
24.44%
7.90%
-0.00%
-3.50%
-3.60%
-3.69%
17.31%
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade
Upgrade